🚀 VC round data is live in beta, check it out!
Mendus Valuation Multiples
Discover revenue and EBITDA valuation multiples for Mendus and similar public comparables like Marinomed Biotech, Radiopharm Theranostics, Outlook Therapeutics, Lipum and more.
Mendus Overview
About Mendus
Mendus AB is a clinical-level biopharmaceutical company based on the company's allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. Its operations consist of research and development for pharmaceuticals. Company Pipeline includes: Vididencel, Ilixadencel, Preclinical.
Founded
2002
HQ
Employees
28
Website
Sectors
Financials (LTM)
EV
$28M
Mendus Financials
Mendus reported last 12-month revenue of $393K and negative EBITDA of ($12M).
In the same LTM period, Mendus generated $393K in gross profit, ($12M) in EBITDA losses, and had net loss of ($12M).
Revenue (LTM)
Mendus P&L
In the most recent fiscal year, Mendus reported revenue of $443K and EBITDA of ($11M).
Mendus expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $393K | XXX | $443K | XXX | XXX | XXX |
| Gross Profit | $393K | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($12M) | XXX | ($11M) | XXX | XXX | XXX |
| EBITDA Margin | (3040%) | XXX | (2546%) | XXX | XXX | XXX |
| EBIT Margin | (3128%) | XXX | (2786%) | XXX | XXX | XXX |
| Net Profit | ($12M) | XXX | ($12M) | XXX | XXX | XXX |
| Net Margin | (3124%) | XXX | (2780%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Mendus Stock Performance
Mendus has current market cap of $34M, and enterprise value of $28M.
Market Cap Evolution
Mendus' stock price is $0.55.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $28M | $34M | 0.7% | XXX | XXX | XXX | $-0.20 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMendus Valuation Multiples
Mendus trades at 72.4x EV/Revenue multiple, and (2.4x) EV/EBITDA.
EV / Revenue (LTM)
Mendus Financial Valuation Multiples
As of April 18, 2026, Mendus has market cap of $34M and EV of $28M.
Equity research analysts estimate Mendus' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mendus has a P/E ratio of (2.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $34M | XXX | $34M | XXX | XXX | XXX |
| EV (current) | $28M | XXX | $28M | XXX | XXX | XXX |
| EV/Revenue | 72.4x | XXX | 64.2x | XXX | XXX | XXX |
| EV/EBITDA | (2.4x) | XXX | (2.5x) | XXX | XXX | XXX |
| EV/EBIT | (2.3x) | XXX | (2.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 72.4x | XXX | — | XXX | XXX | XXX |
| P/E | (2.7x) | XXX | (2.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (3.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Mendus Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Mendus Margins & Growth Rates
Mendus' revenue in the last 12 month grew by 1722%.
Mendus' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.4M for the same period.
Mendus Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1722% | XXX | (38%) | XXX | XXX | XXX |
| EBITDA Margin | (3040%) | XXX | (2546%) | XXX | XXX | XXX |
| EBITDA Growth | (67%) | XXX | (3%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 864% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2273% | XXX | 2153% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 2786% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Mendus Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Mendus | XXX | XXX | XXX | XXX | XXX | XXX |
| Marinomed Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Radiopharm Theranostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Outlook Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Lipum | XXX | XXX | XXX | XXX | XXX | XXX |
| Longeveron | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mendus M&A Activity
Mendus acquired XXX companies to date.
Last acquisition by Mendus was on XXXXXXXX, XXXXX. Mendus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Mendus
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMendus Investment Activity
Mendus invested in XXX companies to date.
Mendus made its latest investment on XXXXXXXX, XXXXX. Mendus invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Mendus
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Mendus
| When was Mendus founded? | Mendus was founded in 2002. |
| Where is Mendus headquartered? | Mendus is headquartered in Sweden. |
| How many employees does Mendus have? | As of today, Mendus has over 28 employees. |
| Who is the CEO of Mendus? | Mendus' CEO is Erik Manting. |
| Is Mendus publicly listed? | Yes, Mendus is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Mendus? | Mendus trades under IMMU ticker. |
| When did Mendus go public? | Mendus went public in 2013. |
| Who are competitors of Mendus? | Mendus main competitors are Marinomed Biotech, Radiopharm Theranostics, Outlook Therapeutics, Lipum. |
| What is the current market cap of Mendus? | Mendus' current market cap is $34M. |
| What is the current revenue of Mendus? | Mendus' last 12 months revenue is $393K. |
| What is the current revenue growth of Mendus? | Mendus revenue growth (NTM/LTM) is 1722%. |
| What is the current EV/Revenue multiple of Mendus? | Current revenue multiple of Mendus is 72.4x. |
| Is Mendus profitable? | No, Mendus is not profitable. |
| What is the current EBITDA of Mendus? | Mendus has negative EBITDA and is not profitable. |
| What is Mendus' EBITDA margin? | Mendus' last 12 months EBITDA margin is (3040%). |
| What is the current EV/EBITDA multiple of Mendus? | Current EBITDA multiple of Mendus is (2.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.